Patents Issued in January 30, 2024
  • Patent number: 11883488
    Abstract: Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: January 30, 2024
    Assignee: Abacus Bioscience, Inc.
    Inventors: Edward A. Clark, Deborah L. Fuller, Che-Leung Law, Amanda Mak
  • Patent number: 11883489
    Abstract: Adjuvants comprising chitosan cross-linked with an aldehyde or mannosylated chitosan are provided herein. Methods of making the adjuvants and methods of combining or linking the adjuvants with antigens are also provided. The adjuvant-antigen combinations can be used in vaccine formulations and the vaccine formulations can be used in methods to vaccinate animals against the source of the antigen or to enhance the immune response in a subject.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: January 30, 2024
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Billy M. Hargis, Neil R. Pumford, Marion Morgan, Srichaitanya Shivaramaiah, Guillermo Tellez-Isaias, Amanda Wolfenden
  • Patent number: 11883490
    Abstract: The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.
    Type: Grant
    Filed: May 20, 2021
    Date of Patent: January 30, 2024
    Assignee: Mirror Biologics, Inc.
    Inventor: Michael Har-Noy
  • Patent number: 11883491
    Abstract: Methods and compositions using an inhibitor of EGFR signaling for prevention or an inhibitor of EGFR signaling and a nucleic acid molecule encoding an atonal-associated factor for treatment of hearing loss are described.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: January 30, 2024
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Jian Zuo, Fei Zheng, Tetsuji Yamashita, Zoe Kellard, Tal Teitz, Jaeki Min, Taosheng Chen
  • Patent number: 11883492
    Abstract: There are provided, inter alia, compositions and methods for treatment of chemoresistant cancer (breast cancer). The methods include administering to a subject in need a therapeutically effective amount of a chemotherapeutic agent and a ROR-1 antagonist. Further provided are pharmaceutical compositions including chemotherapeutic agent, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the chemotherapeutic agent is paclitaxel and the ROR-1 antagonist is cirmtuzumab.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: January 30, 2024
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Thomas Kipps, Suping Zhang, Emanuela M. Ghia
  • Patent number: 11883493
    Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: January 30, 2024
    Assignee: OMEROS CORPORATION
    Inventors: W. Jason Cummings, Gregory A. Demopulos, Thomas Dudler, Larry W. Tjoelker, Christi L. Wood, Munehisa Yabuki
  • Patent number: 11883494
    Abstract: The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.
    Type: Grant
    Filed: March 20, 2023
    Date of Patent: January 30, 2024
    Assignee: MILTENYI BIOTEC B.V. & CO. KG
    Inventors: Michael Lutteropp, Anne Richter, Andrew Kaiser, Mario Assenmacher, Stefan Miltenyi
  • Patent number: 11883495
    Abstract: Provided are anti-CD47 antibodies and fragments thereof. The antibodies and fragments thereof specifically bind to the CD47 protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and atherosclerosis are also provided.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: January 30, 2024
    Assignee: Lepu Biopharma Co., Ltd.
    Inventors: Wenci Gong, Yiwei Tou
  • Patent number: 11883496
    Abstract: A physically stable compositions in the form of an injectable aqueous solution with a pH from 6.0 to 8.0, include a basal insulin whose isoelectric point (pI) is from 5.8 to 8.5, and a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: January 30, 2024
    Assignee: ADOCIA
    Inventors: You-Ping Chan, Alexandre Geissler, Romain Noel, Richard Charvet, Nicolas Laurent
  • Patent number: 11883497
    Abstract: The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: January 30, 2024
    Assignees: PureTech LYT, Inc., Monash University
    Inventors: Daniel Kenneth Bonner, Ketki Karanam, James T. Mutamba, Rishab R. Shyam, Jamie Simpson, Sifei Han, Luojuan Hu, Christopher John Hamilton Porter, Tim Quach, Natalie Trevaskis
  • Patent number: 11883498
    Abstract: The present teachings relate generally to conjugates and methods for imaging a tumor microenvironment in a patient, and to conjugates and methods for treating LHRH-R expressing cancer in a patient. The present teachings relate generally to method of making conjugates comprising an LHRH-R antagonist.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: January 30, 2024
    Assignee: PURDUE RESEARCH FOUNDATION
    Inventors: Philip Stewart Low, Jyoti Roy
  • Patent number: 11883499
    Abstract: Disclosed are conjugate molecules formed from an active agent which is linked to a cannabinoid moiety through a specified linker having ester and amide end groups. The active agent can be a COX-2 inhibitor moiety, and the cannabinoid moiety can be a cannabidiol moiety. These conjugate molecules are contemplated to potentially be effective in the treatment of medical conditions.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: January 30, 2024
    Assignee: AKOS BIOSCIENCES, INC.
    Inventors: Paul M. Hershberger, Yinghui Liu, Kirk William Hering, James Bernard Kramer
  • Patent number: 11883500
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Grant
    Filed: December 2, 2022
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • Patent number: 11883501
    Abstract: The present invention provides a selective CXCR4 binding peptide conjugate (“PC”), and a method for using and producing the same. In particular, the selective CXCR4 binding peptide conjugate of the invention comprises a peptide portion that selectively binds to CXCR4 and a medically useful compound, such as an imaging agent, a diagnostic agent, or a therapeutically or pharmaceutically active compound. In one particular embodiment, the selective CXCR4 binding peptide conjugate (“PC”) is of the formula: or a pharmaceutically acceptable salt thereof, wherein a, b, AA1, AA2, Ar1, X1, and AA3 are those defined herein. The peptide conjugate of the invention can be used in a variety of medical applications including, but not limited to, a targeted drug delivery or imaging a patient or diagnosing a patient for a disease or a clinical condition associated with overexpression and/or upregulation of CXCR4, such as cancers, HIV infection, and immune disorders.
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: January 30, 2024
    Assignee: Mainline Biosciences (Shanghai) Co., Ltd.
    Inventors: Junge Zhang, Liang Zeng Yan
  • Patent number: 11883502
    Abstract: The present invention provides a method of producing a polysaccharide-protein conjugate with capsular polysaccharide from Streptococcus pneumoniae serotype 19F conjugated to a carrier protein. The method includes a prolonged incubation step prior to filtration to remove free polysaccharide.
    Type: Grant
    Filed: December 7, 2021
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael Albert Winters, John E. MacNair
  • Patent number: 11883503
    Abstract: Provided are compositions and methods for treating cancer comprising the use of a immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy shows synergistic effects in cancer treatment.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: January 30, 2024
    Assignee: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting Xu, Yan Luan, Shilong Fu, Songbing Qin, Jian Ding, Kai Fu
  • Patent number: 11883505
    Abstract: Anticancer virus particles are described. Anticancer virus particles are filamentous or rod-shaped plant virus particle containing an anticancer agent within the interior of the virus particle. The anticancer agent can be attached either covalently or non-covalently within the interior of the virus particle. A therapeutically effective amount of an anticancer virus particle can be administered to a subject identified as having cancer to provide a method of cancer treatment.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: January 30, 2024
    Assignees: CASE WESTERN RESERVE UNIVERSITY, MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Nicole F. Steinmetz, Stephen J. Lippard, Anna Czapar, Yaorong Zheng
  • Patent number: 11883506
    Abstract: Provided herein is a gene therapy for PKP2 (Plakophilin-2), e.g. using an adeno-associated virus (AAV) vector. The promoter of the vector may be a MHCK7 promoter or a cardiac troponin T (HTNNT2) promoter. The capsid may be an AAV9 or AAVrh74 capsid or a functional variant thereof. Other promoters or capsids may be used. Further provided are methods of treatment, such as by intravenous, intracoronary, intracarotid or intracardiac administration of the rAAV vector, and other compositions and methods.
    Type: Grant
    Filed: February 11, 2022
    Date of Patent: January 30, 2024
    Assignee: Spacecraft Seven, LLC
    Inventors: Christopher Dean Herzog, Chester Bittencort Sacramento, Raj Prabhakar, David Ricks
  • Patent number: 11883507
    Abstract: The present invention provides an isolated nucleic acid molecule comprising, or consisting of, the nucleic acid sequence of SEQ ID NO:1 or a nucleic acid sequence of at least 300 bp having at least 80% identity to said sequence of SEQ ID NO:1, wherein said isolated nucleic acid molecule specifically leads to the expression in rod photoreceptors of a gene when operatively linked to a nucleic acid sequence coding for said gene.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: January 30, 2024
    Assignee: Friedrich Miescher Institute for Biomedical Research
    Inventors: Dominik Hartl, Josephine Juettner, Arnaud Krebs, Botond Roska, Dirk Schuebeler
  • Patent number: 11883508
    Abstract: The present invention relates to a method for culturing a 3-dimensional lung cancer organoid and a method for preparing a patient-derived xenograft animal model using the same. More specifically, the present invention relates to a method for culturing a 3-dimensional lung cancer organoid, a lung cancer organoid prepared by the method, a medium composition for culturing the lung cancer organoid, a method for preparing a xenograft animal model using the lung cancer organoid, a patient-derived lung cancer organoid xenograft animal model prepared by the method, and a method for analyzing therapeutic efficacy of an anticancer agent and a method for screening an anticancer agent, using the animal model.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: January 30, 2024
    Assignee: ONCOCLEW CO., LTD.
    Inventors: Se Jin Jang, Min Suh Kim, Young Ah Suh, Hye Min Mun, Ju Hee Oh
  • Patent number: 11883509
    Abstract: The present disclosure relates to a method for providing information for determining lung tumor through inhalation of a fluorescent contrast agent, more particularly to a method of inhaling a small amount of Indocyanine green. The present disclosure does not have the problem of the existing intravenous injection that the administered fluorescent contrast agent is distributed throughout the body. In addition, when comparing the cancer detection efficiency of inhalation administration and intravenous injection, the inhaled fluorescent contrast agent exhibits remarkably higher cancer detection effect than the intravenously injected fluorescent contrast agent.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 30, 2024
    Assignees: Korea University Research and Business Foundation, Korea Advanced Institute Of Science And Technology
    Inventors: Hyun Koo Kim, Yuhua Quan, Byeong-Hyeon Choi, Ji-Yun Rho, Ji Ho Park, Ji Young Lim, Chan Hee Oh, Daeho Jung
  • Patent number: 11883510
    Abstract: The present invention relates to a dental composition comprising a photoinitiator system comprising a particulate carrier supporting a coinitiator covalently bonded to the surface of the carrier. Furthermore, the present invention relates to a use of the particulate carrier in a dental composition. The particulate carrier displays multiple covalently bonded tertiary amino groups and/or tertiary phosphine groups on the surface, for crosslinking monomers, oligomers and/or polymers having one or more polymerizable double bonds.
    Type: Grant
    Filed: October 4, 2022
    Date of Patent: January 30, 2024
    Assignee: DENTSPLY SIRONA INC.
    Inventors: Maximilian Maier, Joachim E. Klee, Christian Scheufler, Caroline Renn, Florian Szillat
  • Patent number: 11883511
    Abstract: Disclosed are oral care compositions comprising a thickening silica and a fluoride ion source, wherein fluoride is absorbed on the thickening silica and wherein the pH of the composition is below 5.5, as well as to methods of using these compositions. The thickening silica may have a particle size distribution (D95) less than or equal to 7 ?m and a BET surface area of greater than or equal to 150 m2/g.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: January 30, 2024
    Assignee: GABA International Holding GmbH
    Inventors: Alan Ceresa, Michael Neumann, Madeleine Manns, Nathalie Coq-Bernard, Andre Brunella, Marian Holerca, Thomas Schollbach
  • Patent number: 11883512
    Abstract: The present invention relates to a composition comprising arginine, at least one silicate, at least one alkanolamine, and optionally aqueous ammonia and/or at least one compound which generates aqueous ammonia. The composition further comprises at least one thickening agent chosen from non-associative cellulose polymers, anionic associative polymers, non-ionic associative polymers, and their mixtures. The invention also relates to a method for the treatment of keratin fibres, in particular human keratin fibres, such as the hair, comprising the application of at least one composition according to the invention; and also to the use of the composition according to the invention for the treatment of said keratin fibres, and in particular for the oxidation dyeing and/or the bleaching of the latter.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: January 30, 2024
    Assignee: L'Oreal
    Inventors: Frédéric Guerin, Géraldine Login, Arnaud Hucher
  • Patent number: 11883513
    Abstract: Disclosed is a hair care composition comprising from about 0.04 wt % to about 2 wt % azelaic acid; from about 0.04 wt % to about 1 wt % oleic acid; wherein the ratio of oleic acid to azelaic acid is from about 1:1 to about 1:3.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: January 30, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Jennifer Mary Marsh, Timothy James Felts
  • Patent number: 11883514
    Abstract: Personal care compositions and methods for preparing the same are disclosed. The personal care composition may include an emulsifying system, one or more emollients, and one or more humectants. The method for preparing the personal care composition may include contacting the emulsifying system, the one or more emollients, and the one or more humectants with one another.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: January 30, 2024
    Assignee: Colgate-Palmolive Company
    Inventors: Nadine Dewdney, Christine Boyke
  • Patent number: 11883516
    Abstract: The invention relates to a personal cleansing composition that delivers enhanced deposition of sunscreens on to the topical surface of the body. The composition more particularly provides for such wash off compositions that ensure that the sunscreens incorporated therein are stable and due to the high deposition on to surface provide high Sun Protection Factor (SPF). This is achieved through combination of two select water-soluble sunscreens in a high surfactant containing composition.
    Type: Grant
    Filed: May 31, 2021
    Date of Patent: January 30, 2024
    Assignee: CONOPCO, INC.
    Inventors: Mohini Anand Bapat, Praful Gulab Rao Lahorkar, Rajkumar Perumal, Nikita Tomar, Ashish Anant Vaidya
  • Patent number: 11883517
    Abstract: An external dermal composition and a method for beautifying skin are provided. The external dermal composition mainly includes a double nitrosyl-iron complex and a pharmaceutically acceptable additive. The external dermal composition delivers nitric oxide to a user's skin to beautify the skin when applied to the user's skin.
    Type: Grant
    Filed: January 10, 2022
    Date of Patent: January 30, 2024
    Assignee: NATIONAL TSING HUA UNIVERSITY
    Inventors: Tsai-Te Lu, Chieh-Cheng Huang, Han Chiu, Wei-Ping Wang, Ruei-Ting Wang, Yi-Cian Lai
  • Patent number: 11883518
    Abstract: The subject of the present disclosure is a method for dyeing keratinous material, in particular human hair, comprising the following steps: Application of an agent (a) to the keratinous material, wherein the agent (a) comprises: (a1) at least one organic silicon compound selected from the group of silanes having one, two or three silicon atoms, and (a2) at least one hydroxycarboxylic acid ester, (a3) at least one diol and Application of an agent (b) to the keratinous material, wherein the agent (b) comprises: (b1) at least one sealing reagent, wherein at least one of the agents (a) and (b) further comprises at least one colorant compound selected from the group of pigments and/or direct dyes.
    Type: Grant
    Filed: October 16, 2020
    Date of Patent: January 30, 2024
    Assignee: HENKEL AG & CO. KGAA
    Inventors: Rene Krohn, Thomas Hippe, Jessica Brender, Stefan Hoepfner
  • Patent number: 11883519
    Abstract: Keratin protein cosmetic compositions are provided that include at least one keratin protein derived from human hair and a base cosmetic solution. Methods of treatment are also provided.
    Type: Grant
    Filed: December 22, 2022
    Date of Patent: January 30, 2024
    Assignee: VIRTUE LABS, LLC
    Inventors: Melisse Shaban, William Jacobsen, Erin Falco
  • Patent number: 11883520
    Abstract: Leave-on oral care compositions having good spreadability and improved retention property are provided for promoting Gum Health of a user. Said leave-on oral care compositions comprise a hyaluronic acid or a salt thereof, a polyacrylic acid as a mucoadhesive polymer and an additional polymer.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 30, 2024
    Assignee: The Procter & Gamble Company
    Inventors: Ross Strand, Yang Su, Yunming Shi, Thanigaivel Shanmugam, Guannan Wang, Xiaoxiao Li
  • Patent number: 11883521
    Abstract: The present invention is in the field of rinse-off conditioner compositions; in particular, relates to rinse-off conditioner compositions for hair frizz reduction. Deposition of conditioning materials onto the hair surface results in hair having a greasy feel and look which is undesired. Therefore, there still exists the opportunity to increase the conditioning benefits delivered through hair care compositions, preferably without hair having to look and feel greasy. It is therefore the object of the present invention to provide a conditioning product with superior frizz control even after multiple washes and which does not make the hair look and feel greasy. It has been found that a conditioner composition providing superior frizz control can be obtained using a specific combination of silicones and a tricarboxylic acid.
    Type: Grant
    Filed: October 8, 2019
    Date of Patent: January 30, 2024
    Assignee: Conopco, Inc.
    Inventors: Andrew Malcolm Murray, Anne-Sophie Piggott
  • Patent number: 11883522
    Abstract: It is an object of the present disclosure to provide an agent for coloring keratinous material, in particular human hair, comprising (a1) at least one amino-functionalized silicone polymer, and (a2) at least one pigment, and (a3) at least one phosphorus-comprising organic compound. A second subject matter is a method for dyeing keratin material, wherein the agent is applied to the keratin material.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: January 30, 2024
    Assignee: HENKEL AG & CO. KGAA
    Inventors: Constanze Kruck, Sandra Hilbig, Melanie Moch, Susanne Dickhof, Daniela Kessler-Becker
  • Patent number: 11883523
    Abstract: A method for reducing the appearance of hyperpigmented skin is disclosed. The method can include topically applying to hyperpigmented skin of a person a composition that includes at least one of, at least two of, or all three of (i) an effective amount of Schinus terebinthifolius seed extract, (ii) an effective amount of a mixture comprising Ptychopetalum olacoides bark/stem extract, Pfaffia paniculata root extract, and Trichilia catigua bark extract, and/or (iii) an effective amount of a mixture comprising Himanthalia elongata extract and Undaria pinnatifida extract. Topical application of the composition can reduce the appearance of the hyperpigmented skin.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: January 30, 2024
    Assignee: MARY KAY INC.
    Inventors: Geetha Kalahasti, David Gan
  • Patent number: 11883524
    Abstract: Disclosed is a method of improving a condition or appearance of skin. The method can include applying to skin an effective amount of a topical skin composition comprising tetrahexyldecyl ascorbate, Phyllanthus emblica fruit extract, and tocopherol or tocopherol acetate.
    Type: Grant
    Filed: February 1, 2023
    Date of Patent: January 30, 2024
    Assignee: MARY KAY INC.
    Inventors: Tiffany Carle, Milagros Sanchez, David Gan
  • Patent number: 11883525
    Abstract: The present disclosure provides compositions that enable sustained release of a small molecule tyrosine kinase inhibitor, such as axitinib from a bioerodible polyester polymer implant for the treatment of disease. The composition is especially suitable for treating ophthalmic indications, such as neovascular age related macular degeneration and diabetic macular edema, by intravitreal injection of the implant. The implant is designed to be pre-loaded into a small diameter needle and injected via self-sealing scleral needle penetration at the pars plana. Small molecule tyrosine kinase inhibitors may be released from the implants over a period of one week to three years.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: January 30, 2024
    Assignee: DOSE MEDICAL CORPORATION
    Inventors: Patrick Michael Hughes, James Shiah, Jack Xie, Jia-Ying Yang
  • Patent number: 11883526
    Abstract: The present invention provides methods for treating depression in a patient, comprising administering to the patient in need of the treatment a therapeutically effective amount of esketamine. In some embodiments, the depression is major depressive disorder or treatment resistant depression. In other embodiments, the therapeutically effective amount is clinically proven safe and/or effective. Also provided are methods to mitigate the risk or misuse or abuse of esketamine, instructions for use of the esketamine product, and methods for selling a drug product containing esketamine.
    Type: Grant
    Filed: April 1, 2022
    Date of Patent: January 30, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jaskaran Singh, Ella Daly, Margaret Fedgchin, David Hough, Vanina Popova
  • Patent number: 11883527
    Abstract: The disclosure provides products configured for oral use and methods for preparing such products. In some embodiments, oral products described herein may comprise an active ingredient in an amount of 10 weight percent or less, a sugar alcohol, and a gum, such that the product is in the form of a pastille. In some embodiments, oral products described herein may comprise an active ingredient in an amount of about 10 weight percent or less, a sugar substitute, and a sugar alcohol syrup, such that the product is in the form of a lozenge.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: January 30, 2024
    Assignee: Nicoventures Trading Limited
    Inventors: Darrell Eugene Holton, Jr., Ronald K. Hutchens, Jeremy Barrett Mabe
  • Patent number: 11883528
    Abstract: A pharmaceutical composition for administering directly to the pulmonary tract of a subject includes a salt of triiodothyronine and a pharmaceutically acceptable buffer, adjusted to a pH of 5.5-8.5. The composition can be administered prophylactically or therapeutically to a subject to treat lung inflammation or pulmonary edema.
    Type: Grant
    Filed: August 23, 2022
    Date of Patent: January 30, 2024
    Assignee: Regents of the University of Minnesota
    Inventors: David H. Ingbar, Timothy P. Rich, Robert J. Schumacher, Jianxun Lei, Maneesh Bhargava
  • Patent number: 11883529
    Abstract: Broad cerebrospinal fluid (CSF) distribution of an agent is achievable by delivering the agent in a liquid formulation to the CSF at flow rates less than 500 microliters per hour, such as between about 2 microliters per hour and about 100 microliters per hour.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: January 30, 2024
    Assignee: Medtronic, Inc.
    Inventor: Brian A. Duclos
  • Patent number: 11883530
    Abstract: This invention is directed to a pharmaceutical composition for drinking water administration comprising isoxazoline compounds of formula (I) and a polysorbate surfactant and diethylene glycol monoethyl ether (transcutol); and the use of the composition to treat or prevent parasite infestations of animals.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: January 30, 2024
    Assignee: Intervet Inc.
    Inventors: Anne Lehay, Annie Flochlay-Sigognault
  • Patent number: 11883531
    Abstract: The invention relates to a liquid pharmaceutical composition of Il-2 and its use in the treatment of auto-immune and inflammatory disorders. Methods for preparing said composition and delivery devices filled with said composition are also described.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: January 30, 2024
    Assignee: ILTOO PHARMA
    Inventors: Jérémie Mariau, Michel Thiry
  • Patent number: 11883532
    Abstract: The invention relates to pharmaceutical compositions for parenteral administration comprising a) Ibuprofen or a pharmaceutically acceptable salt thereof, and b) a phosphate buffer.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: January 30, 2024
    Assignee: FRESENIUS KABI AUSTRIA GMBH
    Inventors: Patricia Preissegger, Eva Trotscha
  • Patent number: 11883533
    Abstract: Formulations (e.g., solutions) comprising one or more water-soluble polymer(s), liposomes, and an aqueous carrier, are provided. The provided solutions are useful for rinsing, and/or immersing therein, a contact lens and/or in the treatment of ocular discomfort, for example, an ocular discomfort associated with a contact lens. Also provided are kits comprising the solution and a contact lens; articles-of-manufacturing comprising the solution and configured for dispending the solution; and methods utilizing the solution.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: January 30, 2024
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Jacob Klein, Ronit Goldberg, Jasmine Seror
  • Patent number: 11883534
    Abstract: RNA encoding immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially a neutral surface charge at physiological pH and are effective for immunisation.
    Type: Grant
    Filed: August 8, 2023
    Date of Patent: January 30, 2024
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventor: Andrew Geall
  • Patent number: 11883535
    Abstract: Liposomes termed as small unilamellar vesicles (SUVs), can be synthesized in the 20-50 nm size range, but encounter challenges such as instability and aggregation leading to inter-particle fusion. This limits their use as a therapeutic delivery agent. Increasing the surface negative charge of SUVs, via the attachment of anionic entities such as DNA/RNA, increases the colloidal stability of these vesicles. Additionally, the dense spherical arrangement and radial orientation of nucleic acids exhibits unique chemical and biological properties, unlike their linear counterparts. These liposomal particles, are non-toxic and though anionic, can efficiently enter cells without the aid of ancillary cationic transfection agents in a non-immunogenic fashion. These exceptional properties allow their use as delivery agents for gene regulation in different therapies and offer an alternative platform to metal core spherical nucleic acids.
    Type: Grant
    Filed: September 3, 2020
    Date of Patent: January 30, 2024
    Assignees: NORTHWESTERN UNIVERSITY, EXICURE, INC.
    Inventors: Chad A. Mirkin, Sonbinh T. Nguyen, Resham Singh Banga, Natalia Chernyak, Sergei Gryaznov, Aleksandar Radovic-Moreno, Christopher Mader
  • Patent number: 11883536
    Abstract: A method of preparing polylactic acid (PLA) microsphere and polylactic-co-glycolic acid (PLGA) microsphere is provided, including the following steps. A first solution is provided, including polylactic acid or polylactic-co-glycolic acid and an organic solvent. A second solution is provided, including polyvinyl alcohol, sodium carboxymethyl cellulose and an aqueous solution. The first solution is added to the second solution and, at the same time, the second solution is agitated until polylactic acid is solidified to form a plurality of polylactic acid microspheres, or until polylactic-co-glycolic acid is solidified to form a plurality of polylactic-co-glycolic acid microspheres. The polylactic acid microspheres or polylactic-co-glycolic acid microspheres are collected.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: January 30, 2024
    Assignees: TAIPEI MEDICAL UNIVERSITY, PANION & BF BIOTECH INC.
    Inventors: Ming-Thau Sheu, Yu-Ying Hsu, Yu-De Su, Yu-Hsuan Liu, Pu-Sheng Wei
  • Patent number: 11883537
    Abstract: Described are sustained-release solid dosage forms of epigallocatechin gallate (EGCG) or aminosterol compositions. In one aspect of the invention the sustained-release solid dosage forms of EGCG or an aminosterol are capsules comprising a plurality of coated solid particulates. Another aspect of the invention relates to methods of inhibiting, ameliorating, reducing the likelihood of, delaying the onset of, treating or preventing an amyloid disorder, comprising the step of administering to a subject in need a therapeutically effective amount of the solid dosage form. In certain aspects, the amyloid disorder is Parkinson's Disease.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: January 30, 2024
    Assignee: Axial Therapeutics, Inc.
    Inventors: Ryan Barrett, Hitesh Bhagat, Anthony Stewart Campbell
  • Patent number: 11883538
    Abstract: The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: January 30, 2024
    Assignee: Som Innovation Biotech, S.L.
    Inventors: Anna Nardi Ricart, Josep María Suñé Negre, Núria Reig Bolaño, Raúl Insa Boronat, Oscar Huertas Gambín, Santiago Esteva Gras, Gal⋅Ia Pericot Mohr
  • Patent number: 11883539
    Abstract: The invention provides various novel compositions of berberine in combination with pharmacologically active EPA and DHA, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity. Additionally, the pharmaceutical compositions of the invention are useful in treating and/or preventing atherosclerosis, heart diseases, neurodegenerative diseases, inflammation, cancers, as well as various liver diseases or disorders, such as fatty liver, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestatic liver diseases or graft-versus-host disease of the liver.
    Type: Grant
    Filed: May 15, 2022
    Date of Patent: January 30, 2024
    Assignee: Shenzhen HighTide Biopharmaceutical, Ltd.
    Inventor: Liping Liu